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Abstract
Introduction Laser techniques for the treatment of blad-
der outlet obstruction (BOO) due to benign prostate
enlargement (BPE) have emerged as an alternative to
transurethral resection of the prostate (TURP) and open
prostatectomy (OP).
Materials and methods A Medline search over the past
4 years was performed to assess the safety, intra- and
postoperative morbidity of various laser techniques.
Results Data on holmium laser enucleation of the prostate
(HoLEP) show the highest grade of evidence with two
meta-analyses available and prove the low intra- and
postoperative morbidity with reproducible long-term
results. Photoselective vaporization of the prostate (PVP)
with the Greenlightlaser (potassium titanyl phosphate, KTP
or lithium borate, LBO) is characterized by excellent
haemostatic properties in patients with or without oral
anticoagulation. Long-term results show a reoperation rate
comparable with TURP; however, there is a lack of ran-
domized trials. Various types of diode lasers with different
wavelengths are available for laser vaporization; despite
their favourable haemostatic properties, a higher invasion
depth seems to result in necrosis of the tissue leading to a
higher rate of reoperation. Thulium-laser resection of the
prostate shows promising intra- and postoperative mor-
bidity, but data are limited and initial results need to be
confirmed in large-scale trials.
Conclusion In summary, HoLEP- and KTP-, or LBO-
laser vaporization of the prostate are the most mature
techniques of laser prostatectomy and treatment alterna-
tives to TURP and OP, whereas the clinical value and
durability of procedures with diode laser systems and the
thulium laser need to be confirmed in high-quality pro-
spective RCTs.
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Introduction
Lower urinary tract symptoms (LUTS) due to benign
prostate enlargement (BPE) is a highly prevalent disease.
Nearly 60% of the cohort of the Baltimore Longitudinal
Study of Aging had some degree of clinical BPH by the age
of 60 years [1]. The most common indication for surgery is
LUTS refractory to medical treatment [2]; other indications
include recurrent urinary tract infections, recurrent hae-
maturia, renal insufficiency due to obstruction or bladder
stones [2].
Transurethral resection of the prostate (TURP) is the
gold standard in men with prostates from 30 to 80 ml [2],
while open prostatectomy (OP) is the regarded the treat-
ment of choice in larger sized prostates. TURP can be
associated with complications like bleeding or the
absorption of irrigation fluid (TUR syndrome), which may
have severe consequences like cerebral or bronchial
oedema [3–5]. OP leads to substantial and long-lasting
improvement of voiding parameters and micturition
symptoms; however, it is associated with notable periop-
erative morbidity, a relatively long hospitalization and
limited eligibility for high-risk patients [6–8].
With an ageing population and consecutive increasing
morbidity of urological patients, there is a need for
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minimal-invasive treatment alternatives. In recent years,
various laser techniques have been developed to overcome
complications of TURP and OP while striving to achieve
comparable functional results. Currently, data on HoLEP
and to a minor extent on PVP with the KTP- or LBO-laser
offer a high grade of scientific evidence that these thera-
peutic modalities are recommendable alternatives to TURP
and PVP. Thuliumlaser ablation and diode laser vaporiza-
tion of the prostate are challenging results of HoLEP or
PVP, but further trials are needed to evaluate their clinical
value.
This review focuses on the rate of intra-, perioperative
and long-term complications of each approach alone or in
comparison to TURP or OP to further elucidate their
potential advantages and limitations.
Methods
The data collection is based on a MEDLINE search over
the past 4 years that focused on publications in English
language on HoLEP, PVP with the KTP- or LBO-laser,
thulium-laser prostatectomy and diode-laser prostatectomy.
Levels of evidence were rated according to the latest ver-
sion of the level-of-evidence rating system [9].
Results
Holmium laser enucleation of the prostate
General aspects
The holmium:yttrium–aluminium–garnet (Ho:YAG) laser
is a solid-state pulsed laser. The light produced has a
wavelength of 2,100–2,150 nm and is rapidly absorbed by
water and cell fluid. The penetration depth in prostatic
tissue is 0.4 mm; the resulting high-energy density creates
vaporization without a deep coagulation zone. The pros-
tatic tissue can be precisely incised, dissected and enucle-
ated. With the introduction of a mechanical tissue
morcellator, a rapid development of the enucleation tech-
nique was initiated which has proven to be superior over
the nowadays largely abandoned holmium laser ablation of
the prostate (HoLAP) and holmium laser resection of the
prostate (HoLRP) [10, 11].
Intraoperative complications
Several studies have proven the safety and low intraoper-
ative morbidity of HoLEP. In an extensive review of lit-
erature published between 2003 and 2006 including a total
of 1,847 patients Kuntz [10] reports a low rate of blood
transfusion (1%) and perioperative mortality (0.05%).
Another review shows capsular perforation ranging from
0.3 to 10% which were usually small capsular lacerations
and did not change the subsequent management of patients.
Bladder injury is reported from 0.5 to 18.2% with super-
ficial mucosal injury solely requiring bladder irrigation in
most of the cases. Superficial ureteric orifice injury not
requiring insertion of a ureteral stent or nephrostomy ran-
ges from 1.0 to 2.1%, incomplete morcellation ranges from
1.9 to 3.7% of all cases, and cardiac events were reported
in up to 1.2% of patients undergoing surgery [12]. Analysis
of the occurrence of complications reveals a correlation
with grade of experience of the surgeon [13, 14]. In trained
hands, prostate size had no statistically significant influence
on intraoperative complications [15]. Capsular perforations
are more likely to occur in smaller prostates, while injury
of the ureteric orifice mainly occurs while resecting large
and endovesically growing median lobes [12, 13]. Com-
pared with TURP and OP, patients undergoing HoLEP
have a shorter catheterization time, hospital stay, less blood
loss and fewer blood transfusions at comparable functional
outcome [16–20].
Early postoperative complications
Complications within the first months after HoLEP have
been reported in numerous trials. Haemorrhage needing
coagulation is reported in 0–6% and clot retention in 0–3%
[12]. The reported reoperation rate was 2.9% in a level 1a
metaanalysis and is reported in up to 12% in a level 1b
randomized clinical trial [10, 12]. Postoperative dysuria,
defined as burning and transient urge-incontinence occur
frequently after HoLEP, TURP and OP. In a level 1b
prospective randomized trial comparing HoLEP and OP for
patients with prostates larger than 70 g, at 3-month follow-
up transitory urge-incontinence was equally observed in
34.1% (HoLEP) and 38.6% (OP) of the cases, whereas
dysuria was significantly more frequent in the HoLEP
group (68.2 vs. 41.0%, p \ 0.001) [17]. A multicenter,
prospective, randomized study comparing HoLEP and
TURP showed no significant difference in the reported rate
of transitory urge-incontinence, whereas dysuria occurred
significantly more often in patients after HoLEP (58.9 vs.
29.5%, p = 0.0002) [21]. Early postoperative stress
incontinence occurs as a rare event after HoLEP and is
reported in around 2% of the cases and comparable with
results from TURP and OP [20, 21].
Late complications
In recent years, numerous trials with long-term outcome
of HoLEP were published and have confirmed the long-
lasting and significant improvement of voiding at a low
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complication rate. In an analysis of 38 patients with a
follow-up of 6 years, Gilling et al. report occurrence of
urge-incontinence in three patients, mixed incontinence in
four patients and stress incontinence in one patient. Reop-
eration (HoLEP) was necessary in one patient (1.4%) after
5 years and one patient (1.4%) underwent urethrotomy at
6 months [22]. Comparable long-term results were reported
from other studies with a reoperation rate of 4.2% due to
BPH, urethral strictures (1.7%), meatal stenosis (0.8%) and
bladder neck contracture (0.8%), resulting in a 5-year sur-
gical retreatment-free rate of 92% according to Kaplan–
Meier plot. A comparison of the learning curve showed a
higher retreatment rate in the earlier group of patients (8 vs.
1.4%) [23]. Vavassori et al. [24] observed a reoperation rate
of 2.7% during 36-month follow-up; incidence of urethral
stenosis and bladder neck contracture was significantly
higher in the group of patients with prostates smaller 50 g.
Long-term results and complications of HoLEP in com-
parison with TURP and OP have been reported in recent
years. Reoperation rates in a level 1b prospective, ran-
domized trial were comparable at 3-year follow-up with a
rate of 7.2 and 6.6% for HoLEP and TURP, respectively
[20]. These data are confirmed by other prospective trials
comparing HoLEP to TURP [16]. The long-term safety of
HoLEP for procedures performed in large prostates is
confirmed by prospective, randomized trials comparing
HoLEP to OP. Kuntz et al. observed a reoperation rate at
5-year follow-up of 5 and 6.7% for HoLEP and OP,
respectively [19]. Comparable results are reported from the
24-month follow-up from Naspro et al. [17].
Data on the impact of HoLEP on sexual function are
scarce. It has been previously shown that both HoLEP and
TURP significantly lowered the IIEF orgasmic function
domain due to retrograde ejaculation, while no difference
in overall erectile function was observed [25]. Similar
results were shown in the comparison of HoLEP and OP,
with no significant reduction of erectile function as com-
pared with the baseline preoperative value [17]. Retrograde
ejaculation was reported in 75 and 62% of patients
undergoing HoLEP and TURP, respectively [16].
Photoselective vaporization of the prostate
General aspects
In the early 1990s, visual laser ablation of the prostate with
the 1,064 nm neodymium:yttrium–aluminium–garnet
(Nd:YAG) laser was introduced [26]. The low-absorption
coefficient in most tissues with a penetration depth of 4 and
18 mm resulted in low energy leading to a deep coagula-
tive necrosis of the tissue [10]. Despite intraoperative
safety, improvement of symptoms and voiding parameters
was inferior to TURP, and the rate of reoperations was
considerably higher, so that VLAP has been abandoned
[27, 28]. Passing the Nd:YAG-produced beam (1,046 nm)
through a KTP or LBO crystal, which doubles the fre-
quency and thus halves its wavelength, leads to a green
visible light beam of 532 nm, which has a completely
different laser beam–tissue interaction. The wavelength is
not absorbed by water but strongly absorbed by haemo-
globin, resulting in enhanced haemostatic properties. The
absorption length in vascularized tissue as the prostate is
only 1–3 mm and the high-energy density leads to a rapid
and efficient vaporization of the tissue [29, 30].
Most of the trials published until 2008 are based on the
80-W KTP laser, whereas only limited data are available
on the higher-powered 120-W LBO laser.
Intraoperative complications
Several studies have proven the high intraoperative safety
of photoselective vaporization of the prostate (PVP) alone
[31–33] or in comparison to TURP [34–37] or OP [38] and
in subgroups of patients with large prostates [39, 40], on
anticoagulation [40, 41] or in retention [40, 42]. A level 4
analysis of 500 patients undergoing 80-W KTP PVP
reported intraoperative bleeding in 3.6%, capsule perfora-
tion in 0.2% and conversion to TURP due to bleeding,
prostate size or fibre defect in 5.2% of the patients. No
TUR syndrome was observed and no blood transfusions
were necessary [31]. The high intraoperative safety could
be confirmed for the 120-W LBO-laser with an intraoper-
ative bleeding rate of 1–2.6%, capsule perforation in 1%,
intraoperative blood transfusion in 0.4% and no TUR
syndrome reported [32, 33]. The analysis of intraoperative
complication of patients on anticoagulation, on retention or
with large prostates larger than 80–100 ml showed no
significant difference to the average population of patients
[39–42]. Comparative level 3b studies showed a signifi-
cantly higher rate of transfusion with TURP; the findings
regarding the rate of bleeding are inconsistent with but in
favour of PVP [34–37]. The only currently available level
1b prospective, randomized trial comparing 80-W PVP
with OP for prostates greater than 80 ml showed a signif-
icantly higher rate of perioperative blood transfusions in
the OP group [38].
Early postoperative complications
The rate of early postoperative complications has been
documented in all studies mentioned above [31–36, 38–
42]. Haematuria was reported in 9.8%, blood transfusion in
0.4%, revision in 0.6% acute renal failure in 0.6%, uro-
sepsis in 0.4% dysuria in 14.8%, transient urge-inconti-
nence in 2.4% and urinary tract infection in 6.8% after PVP
with the KTP-laser in a level 4 case series [31]. The
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findings are comparable with results obtained by other
authors [32, 33]. No correlation with the occurrence of
early postoperative complications could be found in
patients in retention, whereas haematuria was significantly
more frequent in patients with anticoagulation (17.2 vs.
5,4%, p = 0.001) [41] and prostates larger than 80 ml
(17.2 vs. 9.8%, p \ 0.05) [31]. Patients with prostates
smaller than 40 ml had a significantly higher rate of dys-
uria than the overall study population (24.3 vs. 14.8%,
p \ 0.01) [31]. Comparing PVP to TURP in patients with
prostates larger than 70 ml, Horasanli et al. observed a
higher rate of urinary retention after PVP (15.3 vs. 2.7%,
p = 0.02) in their level 1b trial. This is in contrast to non-
randomized trials in patients with prostates smaller than
70 ml [35, 36]. A significant higher rate of haematuria with
transient bladder irrigation and clot retention was observed
after TURP in a non-randomized trial, while the rate of
revision, blood transfusion, acute renal failure, dysuria and
urinary tract infection were comparable [35]. No difference
in the incidence of postoperative complications was doc-
umented in the level 1b prospective randomized trial
comparing PVP to OP for prostatic adenomas greater than
80 ml [38].
Late complications
One of the major limitations in evaluating the longevity and
long-term morbidity of PVP is the current lack of long-term
data from level 1b randomized trials. The longest follow-up
with the highest number of patients was reported by a level
4 case series Hai. Of 246 patients available for analysis at 5-
year follow-up after PVP, 19 (7.7%) had to be retreated with
PVP due to recurrent adenoma and three (1.2%) underwent
incision of the bladder neck resulting in an overall retreat-
ment rate of 8.9% [43]. These data are comparable with
results from a level 4 case series from our own centre with a
retreatment rate of 14.8% due to recurrent or persisting
adenoma tissue (6.8%), bladder neck strictures (3.6%) or
urethral strictures (4.4%); however, only 27 patients were
available at 5-year follow-up [31]. Anticoagulation and
urinary retention at the time of surgery have no significant
influence on the rate of long-term complications [41, 42].
The efficacy of PVP in patients with larger prostates seems
to be reduced. In their level 1b prospective randomized trial,
Horasanli et al. observed a reoperation rate of 17.9% within
6-month follow-up after PVP in patients with prostates
larger than 70 ml due to persisting tissue, whereas no re-
intervention was necessary in the TURP group. Further-
more, the functional outcome was superior in the TURP
group. In a level 2b prospective multicenter study, a
decreased efficacy of PVP in patients with larger prostates
and PSA levels C6.1 ng/ml could be demonstrated [44]. In
contrast, level 4 case series showed that the retreatment rate
due to recurrent adenoma was not higher in patients with
large prostates. However, these studies lack a comparison to
TURP or OP [31, 39]. The rate of bladder neck strictures
was significantly higher in patients with prostates smaller
40 ml (7.8 vs. 3.6%, p \ 0.05) [31, 39]. Results from non-
randomized trials comparing PVP and TURP show no
significant difference in the rate of urethral strictures,
bladder neck strictures or reoperation due to recurrent
adenoma [35, 36]. The level 1b trial comparing OP to 80-W
PVP found no difference regarding recatheterization or
reoperation at comparable functional outcome; however,
longer follow-up needs to be awaited taking into account an
observation period of only18 months [38].
Data on sexual function after PVP are limited. Com-
paring preoperative and 12-month post-operative sexual
function in men undergoing PVP, sexual function was
maintained in patients who were catheter free or performed
intermittent catheterization and improved for patients
with indwelling catheters preoperatively [45]. A general
improvement of sexual function and erectile function was
observed in the 6-month follow-up of another study [46].
The rate of retrograde ejaculation is comparable between
TURP and PVP (56.7 vs. 49.9%, p = 0.21) [34], and no
difference can be detected between patients undergoing OP
and PVP concerning erectile function [38].
Diode-laser prostatectomy
General aspects
Various types of diode lasers operating at wavelengths of
940, 980 or 1,470 nm are available for the application in
diode-laser prostatectomy. A preclinical trial performed on
the established ex vivo model of the blood-perfused porcine
kidney has shown a higher tissue ablation capacity, similar
haemostasis and smaller coagulation zone of the 980-nm
diode laser compared with the KTP-laser [47]. In contrast,
ex vivo studies with a 1,470-nm 50-W diode laser showed a
significantly lower capacity of tissue ablation and a signif-
icantly larger coagulation zone compared with the 80-W
KTP-laser; in an ex vivo setting the mean coagulation zone
of a 940-nm diode laser was 4.25 mm [48, 49]. Currently,
only a few studies investigated the clinical applications and
with a maximum follow-up of 1 year. Further studies are
essential to further evaluate the technique.
Intraoperative complications
Currently, clinical data are available on 980- and 1,470-nm
diode-laser [50–52]. All studies, either level 3b or 4, show
a high intraoperative safety of the diode laser. In a com-
parison between the safety and efficacy of the 980-nm
diode laser and the 120-W Greenlight laser, the rate of
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intraoperative bleeding was significantly lower in the
diode-laser group (0 vs. 13%, p \ 0.01) despite anticoag-
ulation in 51% of all patients. Furthermore, no capsule
perforation was reported, and a conversion to TURP was
necessary in 4% of the cases [50].
Early postoperative complications
The incidence of early postoperative complications repor-
ted in the literature is low; however, the limited amount of
data available on the technique has to be taken into
account. No postoperative blood transfusions occurred, the
rate of dysuria was between 20 and 24%, urinary tract
infection was reported in 11%, and the recatheterization
rate was up to 20%. [50, 51]. Compared with the 120-W
Greenlight laser, the rate of transient urge-incontinence
was significantly higher [50].
Late complications
The rate of late complications reported in the current liter-
ature seems to be remarkably high after diode-laser pro-
statectomy. Within a follow-up of 12 months, reoperation
was necessary in 32.1% of patients after laser-prostatecto-
my with the 980-nm diode laser due to obstructive necrotic
tissue or bladder neck stricture. Furthermore, persisting
incontinence occurred in 10.7% of the patients [53]. After
treatment with a 1,470-nm diode laser, re-TURP was nec-
essary in 20% of patients within 1-year follow-up [51].
Thulium-laser prostatectomy
General aspects
The thulium:yrrtium–aluminium–garnet (Tm:YAG) laser
operates at a wavelength of 2 lm and is delivered as a
continuous wave (CW). The wavelength is close to the
absorption peak of water and the short penetration depth
results in a high-energy density leading to rapid vaporiza-
tion of the tissue. Ex vivo experiments performed on blood-
perfused porcine kidneys showed that the 2-lm CW thu-
lium-laser offers a higher tissue ablation capacity and
comparable haemostatic properties with the KTP laser [54].
Two different techniques have been described for the
application of the thulium-laser in prostate surgery: enu-
cleation of the prostate [55–57] comparable to HoLEP and
vaporesection of the prostate [58, 59].
Intraoperative complications
The rate of intraoperative complications occurring during
vaporesection or enucleation with the thulium-laser is low.
Intra- or early postoperative bleeding was reported in 3.4%
of the patients undergoing enucleation of the prostate and
the rate of blood transfusions was up to 2.2% [55,
56].Transfusions or occurrence of TUR syndrome are not
reported during or after vaporesection of the prostate,
whereas in a level 1b prospective randomized trial blood
transfusion was necessary in 4.2% with TURP, and TUR
syndrome occurred in 2.1% of the patients [58, 59].
Early postoperative complications
In the early postoperative course after thulium enucleation
of the prostate, symptomatic urinary tract infection occurred
in 6.8%, a second-look procedure during hospitalization
was necessary in 2.2% and recatheterization occurred in
1.1% [55]. Comparing the complications of patients with in
retention with patients without preoperative indwelling
catheter prior to enucleation of the prostate, a significantly
higher rate of postoperative haematuria and urinary tract
infection was observed in patients in retention [56]. The rate
of urinary tract infections after thulium-vaporesection of the
prostate ranges from 3.9 to 11.1%. In the current literature,
no recatheterization after this intervention is described;
transitory urge-incontinence seems to occur less frequently
than after TURP (23.1 vs. 31.3%, p = 0.36) [58, 59].
Late complications
In the current literature, data with a follow-up of more than
12 months after thulium-laser prostatectomy are available.
Within the follow-up after thulium-laser enucleation,
transient recatheterization was necessary in up to 5.6% of
patients, reoperation occurred in 2.8–3.4% of all patients
and voiding symptoms and micturition parameters showed
a significant improvement [56, 57]. Within a 1-year follow-
up after thulium-vaporesection of the prostate in 54 men no
reoperation was needed in the series of Bach et al. Com-
paring thulium-vaporesection to TURP, the rate of retro-
grade ejaculation (55%), urethral stricture (1.9%) and
stress incontinence (none) shows no significant difference
[59]. Despite the encouraging results of this technique,
further studies are required to confirm these data.
Discussion
For several years, TURP and OP have been considered as
gold standard in the treatment of BOO due to BPE. Despite
their proven clinical outcome, the rate of intraoperative and
postoperative morbidity led to the development of alter-
native surgical methods seeking to produce equal func-
tional results at a lower rate of intra- and postoperative
complications. One of the limitations in the analysis of the
incidence of complications is that often no classification is
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available or classifications are not used by authors. Several
laser types with different wavelengths and consequently
different physical properties have been developed in recent
years. Tables 1, 2 and 3 summarize complications after
various techniques of laser prostatectomy in comparison
with landmark publications on TURP and OP, demon-
strating especially the high intraoperative safety of laser
techniques. However, long-term results from some tech-
niques are scarce, the number of patients in studies often is
limited and a remarkably high reoperation rate within a
relatively short follow-up is reported from some laser
types. Furthermore, underreporting of complications due to
loss of follow-up data or insufficient documentation could
lead to a bias in clinical studies, making a comparison of
various techniques difficult.
The most mature technique for laser prostatectomy is
HoLEP. Mimicking OP, the procedure leads to an almost
complete removal of tissue leading to a long-lasting
improvement of symptoms and micturition parameters.
Several trials have proven the intraoperative safety of the
technique, showing that patients undergoing HoLEP have a
shorter catheterization time, hospital stay, less blood loss
and fewer blood transfusions than patients with TURP or
OP. During early postoperative follow-up, dysuria is
reported more frequently after HoLEP than after OP or
TURP. It has to be taken into consideration that these
symptoms are primarily self-limiting, rarely requiring
medical treatment. Furthermore, definitions of dysuria are
often imprecise, ranging from simple burning to alguria.
Long-term complications of HoLEP are low and compara-
ble with TURP or OP, supporting the maturity of HoLEP as
a real therapeutic alternative to the current gold standard.
Despite the excellent intra- and postoperative safety,
HoLEP is primarily restricted to a few centres of
Table 1 Comparison of intraoperative complications after various laser prostatectomies to TURP and OP in recent series
Author Year Ref. no. No. of
patients
Follow-up
(month)
Intraoperative complications (%)
Blood
transfusion
Capsular
perforation
Bladder/ureteric
orifice injury
HoLEP
Montorsi 2008 [21] 52 12 0 – 18.2
Naspro 2006 [17] 41 24 4.0 – 7.3
Placer 2009 [13] 125 24 0.8 10.4 4.0
Shah 2007 [12] 280 24 0.35 9.6 6.0
Vavassori 2008 [24] 330 36 – – 5.7
Wilson 2006 [16] 30 24 0 – –
PVP
Bouchier-Hayes 2006 [37] 76 12 0 – –
Choi 2008 [33] 305 6 0.4 1.0 –
Horasanli 2008 [34] 39 6 0 0 –
Rajbabu 2007 [39] 54 24 – – 1.8
Ruszat 2008 [31] 500 60 0 0.2 –
Ruszat 2008 [35] 269 24 0 0.4 –
Skolarios 2008 [38] 65 18 0 – –
Spaliviero 2009 [32] 70 12 0 0 0
Diode laser vaporization
Rieken 2009 [60] 56 12 0 0 0
Seitz 2007 [51] 10 12 0 0 0
Thulium-laser vaporesection/laser enucleation
Bach 2007 [58] 54 12 0 – –
Bach 2009 [56] 208 1 0.9 – –
Xia 2008 [59] 52 12 0 – –
Median laser techniques 65 12 0 0.2 4.0
TURP
Reich 2008 [60] 10,654 \1 2.9 – –
OP
Gratzke 2007 [61] 902 \1 7.5 – –
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excellence with high expertise. This is supported by data,
showing a positive correlation between experience of the
surgeon and rate of complications. The steep learning curve
and complexity of the technique anticipate are widespread
application of the technique.
In contrast to HoLEP, PVP with the KTP- or LBO-laser
is a TURP-like technique relatively easy to learn.
Enhanced by marketing, the flat learning curve leads to a
widespread use of the technique. Due to its specific phys-
ical properties, the procedure is performed in an almost
blood-less setting, allowing surgery in high-risk patients
under anticoagulation and with large prostates. Intraoper-
ative morbidity is low and early postoperative complica-
tions comparable to OP or TURP. One of the major
limitations in the evaluation of the longevity and long-term
morbidity of PVP is the current lack of data, especially
long-term results from level 1b prospective, randomized
trials. Long-term data include only limited patient number,
so that a final evaluation of the technique regarding its
long-term durability could not be drawn from currently
available scientific evidence.
Diode-laser prostatectomy and thulium-laser vaporiza-
tion or enucleation of the prostate are recently introduced
surgical applications of the laser technology. A general
limitation is the lack of large-scale prospective randomized
trials with these lasers, making a final evaluation impos-
sible. Diode lasers show excellent haemostatic properties
superior to PVP in ex vivo experiments as well as in
clinical application. However, a relatively high number of
transient urge and reoperations is observed after surgery.
The reason is presumably a relatively high invasion depth
of the laser energy, leading to damage and necrosis in the
underlying tissue. Future technological developments of
diode lasers need to overcome these limitations in order to
produce long-lasting surgical results. The application of the
thulium-laser shows encouraging intra- and postoperative
complications. The number of studies which have been
conducted with this laser type is limited and the follow-up
Table 2 Comparison of early postoperative complications after various laser prostatectomies in recent series
Author Year Ref. no. No. of
patients
Follow-up
(months)
Early postoperative complications (%)
Transitory urge/
storage symtoms
Dysuria Recatheterization
HoLEP
Montorsi 2008 [21] 52 12 44.0 58.9 –
Naspro 2006 [17] 41 24 34.1 68.2 –
Placer 2009 [13] 125 24 19.2 2.4 –
Shah 2007 [12] 280 24 10.7 – 3.9
Vavassori 2008 [24] 330 36 28.0 – –
Wilson 2006 [16] 30 24 – – 17.0
PVP
Bouchier-Hayes 2006 [37] 76 12 10.5 – 3.9
Choi 2008 [33] 305 6 – 11.8 4.6
Horasanli 2008 [34] 39 6 – – 15.3
Rajbabu 2007 [39] 54 24 5.5 – –
Ruszat 2008 [31] 500 60 2.4 14.8 –
Ruszat 2008 [35] 269 24 – 13.0 –
Skolarios 2008 [38] 65 18 – 7.6 10.7
Spaliviero 2009 [32] 70 12 8.6 – –
Diode laser vaporization
Rieken 2009 [60] 56 12 30.3 – 19.6
Seitz 2007 [51] 10 12 – 20.0 20.0
Thulium-laser vaporesection/laser enucleation
Bach 2007 [58] 54 12 – 10.7 0
Bach 2009 [56] 208 1 – – 3.8
Xia 2008 [59] 52 12 23.1 – 0
Median laser techniques 65 12 19.2 13.0 4.6
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still is too short to draw further conclusions about the
durability of the procedure. However, results available are
encouraging, and future trials will define the clinical sig-
nificance of the technique.
Conclusions
In recent years, scientific evidence from various studies
has proven the intraoperative safety of PVP and HoLEP.
Long-term data confirm the safety and durability of HoLEP,
challenging the established gold standard TURP and OP.
One major limitation for the spread of HoLEP is the steep
learning curve, restricting HoLEP to specific centres. Long-
term data from prospective, randomized trials are still
necessary to evaluate the longevity of PVP and define its
role in the treatment of BPE. Diode-laser and thulium-laser
prostatectomy are in an early stage of clinical evaluation.
Despite encouraging results, further data from high-quality
RCTs are needed to define their therapeutic role.
Table 3 Comparison of late complications after various laser prostatectomies to TURP and OP in recent series
Author Year Ref. no. No. of
patients
Follow-up
(month)
Late complications (%)
Persisting urge/
stress incontinence
Urethral
stricture
Bladder neck
contracture
Reoperation for
recurrent tissue
HoLEP
Ahyai 2007 [20] 100 36 – 4.1 3.1 1.0
Elzayat 2007 [23] 118 72 – 1.7 0.8 4.2
Gilling 2008 [22] 38 72 – 1.4 0 1.4
Kuntz 2008 [19] 60 60 – 3.3 1.7 0
Montorsi 2008 [21] 52 12 1.7 1.7 – –
Naspro 2006 [17] 41 24 5.4 a 7.3a –
Placer 2009 [13] 125 24 – 1.6 4.0 0.8
Shah 2007 [12] 280 24 0.7 2.1 0.4 0
Vavassori 2008 [24] 330 36 0.6 3.0 0.6 2.7
Wilson 2006 [16] 30 24 3.3 3.3 0 0
PVP
Bouchier-Hayes 2006 [37] 76 12 – 0 0 5.6
Hai 2009 [43] 321 60 – – 1.2 7.7
Horasanli 2008 [34] 39 6 – 5.1 – 17.9
Rajbabu 2007 [39] 54 24 – – – 3.7
Ruszat 2008 [31] 500 60 1.2 4.4 3.6 6.8
Ruszat 2008 [35] 269 24 – 4.5 4.5 6.7
Skolarios 2008 [38] 65 18 – b b 4.62b
Spaliviero 2009 [32] 70 12 0 0 0 0
Diode laser vaporization
Rieken 2009 [60] 56 12 10.7 – 12.5 19.6
Seitz 2007 [51] 10 12 – 0 0 20.0
Thulium-laser vaporesection/laser enucleation
Bach 2007 [58] 54 12 – 0 0 0
Bach 2009 [57] 88 16.5 – 1.1 0 2.2
Xia 2008 [59] 52 12 0 1.9 0 0
Median laser techniques 65 24 1.2 1.8 0.6 2.7
TURP
Madersbacher 2005 [62] 20,671 96 – c 7.3c 7.4
OP
Madersbacher 2005 [62] 2,452 96 c 6.1c 3.4
a Bladder neck contractures and urethral strictures after 24-month follow-up
b Reoperation due to urethral stricture, bladder neck contracture and apical resection after 18-month follow-up
c Cumulative incidence of a secondary endoscopic intervention (urethrotomy, bladder neck incision) after 96-month follow-up
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